InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
83.19
(
0.07%
)
Bitcoin
64,136.06
(
0.21%
)
Post# of 84
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

81vette

Send PM Follow Ignore
Followers 81
Posts 6373
Boards Moderated 4
Alias Born 01/14/2015

81vette

Re: None

Tuesday, 01/10/2023 11:05:53 AM

Tuesday, January 10, 2023 11:05:53 AM

Post# of 84
2023 plan>Present the first detailed results from the Targeted Therapeutics program device performance study indicating successful device function when administered with food, which could potentially enable non-fasted administration in patients, at the Crohn’s & Colitis Congress on January 19, 2023.
File an IND for Targeted Therapeutics PGN-600 and enter the clinic in the first half of 2023.
Generate key Targeted Therapeutics PGN-600 data by Q3.
Complete Systemic Therapeutics preclinical data generation with the next generation device in Q1 and Q2.
Initiate next-phase pharma partnerships for Systemic Therapeutics program in 2023.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up